<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403141</url>
  </required_header>
  <id_info>
    <org_study_id>IREC020</org_study_id>
    <nct_id>NCT02403141</nct_id>
  </id_info>
  <brief_title>Abu Dhabi Sleep Apnea (ADSA) Study</brief_title>
  <acronym>ADSA</acronym>
  <official_title>Abu Dhabi Sleep Apnea (ADSA) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London Diabetes Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London Diabetes Centre</source>
  <brief_summary>
    <textblock>
      Obstructive sleep apnoea (OSA) is a common medical problem which, despite increasing
      awareness, remains under-diagnosed. There is a close association between OSA and obesity;
      60-70% of patients diagnosed with OSA are either obese or overweight [1]. OSA is also very
      common among patients with type 2 diabetes. Type 2 Diabetes Mellitus (T2DM) has reached
      epidemic status in the Gulf region. OSA worsens insulin resistance and leads to weight gain
      through sleep disturbance [2]. Several mechanisms have been proposed for the associations of
      OSA with diabetes and obesity [3]. At present there is little available information regarding
      the prevalence of OSA in the UAE, the relationship with T2DM and obesity, and the impact of
      OSA on health outcomes in the Emirati population. This research will explore these
      relationships and inform public health decisions regarding diagnostic pathways, service
      provision and treatment protocols.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective (Establishing the prevalence of OSA in the study population.)</measure>
    <time_frame>3 months</time_frame>
    <description>Establishing the prevalence of OSA in the study population.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Sleep Apnoea</condition>
  <arm_group>
    <arm_group_label>Normal glucose tolerance</arm_group_label>
    <description>Patients with normal fasting glucose. Blood glucose less than 5.6mmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Impaired fasting glycaemia</arm_group_label>
    <description>Patients with blood glucose between 5.6mmol/L - 7mmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <description>Patients with blood glucose higher than 7mmol/L and negative IA2 and GAD antibodies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 1 diabetes</arm_group_label>
    <description>Patients on insulin and with positive IA2 and/or GAD antibodies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <arm_group_label>Normal glucose tolerance</arm_group_label>
    <arm_group_label>Impaired fasting glycaemia</arm_group_label>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <arm_group_label>Type 1 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over the age of 18 attending ICLDC will be offered the option of taking part in
        the study. Those agreeing to participate will be asked to fill in a questionnaire.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants aged between 18-64 years old. Both Gender male and female.

        Exclusion Criteria:

        Paediatrics below the age of 18. Any participant who is unable to take part
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Imperial College London Diabetes Centre</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>P.O Box 48338</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Imperial College London Diabetes Centre</investigator_affiliation>
    <investigator_full_name>Dr Nader Lessan, MD</investigator_full_name>
    <investigator_title>Consultant Endocrinologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

